6-KThe Wire
TAKEDA PHARMACEUTICAL CO LTD files 6-K
Filed May 26, 2026 · 1mo ago · Accession 0001395064-26-000158
Plain English
Takeda Pharmaceutical Company Limited announced a shareholder letter from CEO-Elect Julie Kim, providing an update on the company's strategic direction and business performance. The letter highlights Takeda's focus on its growth drivers and commitment to delivering value to shareholders.
Filing details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Ticker
- TAK
- CIK
- 1395064
- Form type
- 6-K
- Filing date
- May 26, 2026
- Report date
- May 26, 2026
- Document
- form6k_052626x3.htm
- Size
- 1.5 MB